Just caught that RAPT Therapeutics added two solid names to their board - Scott Braunstein and Ashley Dombkowski. Dombkowski especially caught my eye because she's got serious food allergy expertise, which is exactly where RAPT's trying to go with RPT904. She's literally built companies around this space before, so it's not random board padding.

Braunstein's background is pretty deep too - spent years in healthcare investing and ran pharma ops at bigger companies. Both of them joining as RAPT's pushing RPT904 into Phase 2 for food allergy later this year feels strategic. Like they're bringing in people who actually know how to scale these allergic disease treatments.

What's interesting is the timing - they're also running trials for chronic urticaria and asthma with the same candidate. Dombkowski mentioned the 'pipeline-in-a-product' angle, which basically means one drug hitting multiple indications. That's the dream scenario for biotech. Not sure if the market's pricing that in yet, but having experienced operators like Ashley Dombkowski on the board probably signals management thinks they're onto something real here.